Eyelid Tumors

The eyelid is a complex structure made up of several distinct tissue layers—skin and fat on the outer surface, a sheet of muscle that opens and closes the lid (the orbicularis oculi), a firm internal plate of cartilage-like tissue that contains the meibomian oil glands (the tarsus), and a moist inner lining that contacts the eye (the palpebral conjunctiva). Because each of these layers contains different types of cells, growths can arise from any one of them. These growths are collectively called periocular neoplasms or eyelid tumors. They range from entirely harmless skin tags and cysts to aggressive cancers that, if left untreated, can invade the eye socket and surrounding structures. Identifying and correctly classifying an eyelid growth—whether benign or malignant—is essential because it determines the urgency and type of treatment needed.

Eyelid tumors are abnormal growths—either benign (noncancerous) or malignant (cancerous)—that develop from any of the tissue layers of the eyelid. Eyelid cancers account for approximately 5–10% of all skin cancers and about 15% of all facial tumors. Despite this, the majority of eyelid tumors are benign—in large studies of eyelid lesions, roughly 86% have been found to be noncancerous, about 13% malignant, and a small percentage premalignant (meaning they carry a risk of becoming cancerous over time if untreated). Benign lesions tend to be diagnosed at a younger average age than malignant ones.

Most eyelid tumors grow slowly and are detected either by the patient or during a routine eye exam. While benign tumors rarely cause serious harm, malignant eyelid tumors—if not caught and treated early—can spread to the eye socket, the sinuses, the lymph nodes, and in some cases to distant organs. Early evaluation of any new or changing eyelid growth by an ophthalmologist or oculoplastic surgeon (a specialist in the tissues around the eye) is important. The incidence of certain eyelid skin cancers, particularly squamous cell carcinoma, has increased significantly over recent decades, making awareness of warning signs more important than ever.

Eyelid tumors are classified by the type of tissue they arise from and whether they are benign, premalignant, or malignant. The following are the most clinically important types:

• Squamous papilloma: the most common benign epithelial (skin-origin) eyelid tumor. It appears as a soft, flesh-colored growth—either on a stalk (pedunculated) or sitting flat on the skin—with a bumpy, wart-like surface. It is harmless but can be removed if it causes irritation or cosmetic concern.
• Seborrheic keratosis: a very common benign growth in middle-aged and older adults. It appears as a well-defined, warty, waxy plaque with a stuck-on appearance. It is not cancerous and does not require treatment unless it becomes irritated or the diagnosis is uncertain.
• Epidermal inclusion cyst (epidermoid cyst): a smooth, dome-shaped bump filled with keratin (a skin protein). It is not cancerous. It can be left alone or surgically removed if it grows, becomes inflamed, or is cosmetically bothersome.
• Dermoid cyst: a congenital cyst (present from birth) that most commonly appears on the upper outer eyelid near the brow in children and young adults. It contains skin components such as hair, oil, and keratin. It is benign but requires surgical removal to prevent rupture and inflammation.
• Melanocytic nevus (mole): the most common benign eyelid lesion in many populations. A nevus is a cluster of pigmented cells. Eyelid moles may be flat or raised, range from pink to dark brown, and are entirely benign. They should be monitored for changes in size, shape, or color that could signal transformation to melanoma.
• Keratoacanthoma: a rapidly growing, dome-shaped nodule with a central crater filled with keratin. It may look very similar to squamous cell carcinoma on examination and is treated as such, since the two can be difficult to distinguish without a tissue biopsy.
• Basal cell carcinoma (BCC): —the most common malignant eyelid tumor, accounting for the large majority of all eyelid cancers. It most often appears as a painless, pearly or flesh-colored nodule with rolled edges and small blood vessels visible on the surface, often with a central depression or ulcer. BCC typically occurs on the lower eyelid. While it grows slowly and rarely spreads to other organs, it can invade deeply into surrounding tissues if left untreated. Sun exposure is the primary cause.
• Squamous cell carcinoma (SCC): the second most common malignant eyelid tumor. It may appear as a scaly, red or crusted patch, an ulcerated nodule, or a rapidly growing firm lesion. SCC is more aggressive than BCC and has a greater capacity to spread to lymph nodes and distant organs. It may arise from a premalignant lesion called actinic keratosis. Its incidence has increased substantially over recent decades.
• Sebaceous gland carcinoma (SGC): a rare but aggressive malignancy arising from the meibomian glands or other sebaceous (oil-producing) glands of the eyelid. It is the third most common malignant eyelid tumor and has a reputation as a masquerader—it often mimics benign conditions such as a chalazion (an eyelid lump from a blocked meibomian gland) or chronic blepharitis (eyelid inflammation), leading to delayed diagnosis. SGC is more common in older women and in people of Asian descent. It carries the highest mortality rate among common eyelid cancers if not caught early.
• Malignant melanoma: an uncommon but highly dangerous malignancy arising from pigment-producing cells (melanocytes) in the eyelid skin. It may appear as a changing, irregularly shaped, darkly or variably pigmented lesion. Eyelid melanoma requires urgent evaluation and carries a significant risk of spreading through the lymphatic system and bloodstream.
• Merkel cell carcinoma: a rare but aggressive neuroendocrine (nerve and hormone cell-related) skin cancer that can occur on the eyelid. It tends to appear as a rapidly growing, firm, red-purple nodule. It has a high rate of local recurrence and regional spread.
• Kaposi sarcoma: a vascular (blood vessel) tumor associated with human herpesvirus 8 (HHV-8) and immunosuppression, most commonly in people with human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS). On the eyelid, it may appear as a purple-red, soft, painless lesion on the conjunctiva or eyelid skin.

Eyelid tumors develop when the normal regulation of cell growth in one of the eyelid’s tissue layers breaks down, causing cells to divide and accumulate abnormally. The specific cause depends on the tumor type. For the most common malignant eyelid tumors—basal cell carcinoma and squamous cell carcinoma—ultraviolet (UV) radiation from the sun is the primary driver. UV light damages the deoxyribonucleic acid (DNA) inside skin cells, and over years and decades of cumulative exposure, these damaged cells can lose the ability to control their own growth and become cancerous. The lower eyelid is particularly vulnerable because it receives more direct sunlight than the upper lid.

Other important causes and contributing factors include:

• Ultraviolet radiation: Long-term exposure to sunlight or artificial UV sources (such as tanning beds) is the leading cause of basal cell carcinoma and squamous cell carcinoma of the eyelid.
• Radiation exposure: Prior radiation therapy to the head or face increases the long-term risk of skin cancers at the treated site.
• Human papillomavirus (HPV): Certain strains of HPV are associated with squamous papillomas and some cases of squamous cell carcinoma of the eyelid.
• Immunosuppression: People whose immune systems are suppressed—due to HIV infection, organ transplant medications, or certain cancer treatments—face a significantly higher risk of skin cancers and Kaposi sarcoma of the eyelid.
• Genetic predisposition: Several inherited conditions markedly increase eyelid cancer risk. Xeroderma pigmentosum is a rare genetic disorder that impairs the body’s ability to repair UV-induced DNA damage, leading to a very high rate of skin cancers in sun-exposed areas, including the eyelids. Gorlin syndrome (basal cell nevus syndrome) is an inherited condition characterized by multiple basal cell carcinomas from a young age. Muir-Torre syndrome predisposes to sebaceous gland carcinoma alongside internal cancers.
• Fair skin, light eyes, and light hair: These features are associated with reduced melanin protection and higher UV-related skin cancer risk.
• Chronic inflammation: Long-standing inflammatory conditions of the eyelid, such as blepharitis or a repeatedly recurring chalazion, can, in rare cases, be associated with the development of sebaceous gland carcinoma.
• Age: Most malignant eyelid tumors occur in older adults, reflecting the cumulative effect of decades of UV exposure and cellular aging.

Anyone can develop an eyelid tumor, but the following factors are associated with a higher likelihood of developing a malignant eyelid growth in particular. Many of these risk factors are the same as those for skin cancer elsewhere on the body.

• Older age: Malignant eyelid tumors are diagnosed most commonly in people over age 60, though they can occur in younger adults, particularly in those with genetic risk factors or immunosuppression.
• Fair skin, light eyes, or light hair: People with less melanin in their skin have less natural protection against UV radiation damage.
• Prolonged or occupational sun exposure: People who spend many years outdoors—such as farmers, construction workers, and sailors—accumulate more UV damage over a lifetime.
• History of skin cancer: Having a prior basal cell carcinoma, squamous cell carcinoma, or melanoma anywhere on the body raises the risk of developing another skin cancer, including on the eyelid.
• Immunosuppression: People living with HIV, organ transplant recipients on immunosuppressive medications, or those undergoing immunosuppressive cancer treatments face a substantially elevated risk of skin malignancies.
• Genetic syndromes: Xeroderma pigmentosum, Gorlin syndrome, and Muir-Torre syndrome each dramatically increase the risk of eyelid malignancy.
• Asian and South Asian ethnicity: Sebaceous gland carcinoma is more common in people of Asian descent compared to Western populations, for reasons that are not fully understood.
• Failure to use sun protection: Not wearing UV-protective sunglasses, hats, or sunscreen consistently over many years is a major modifiable risk factor.

There is no formal population-wide screening program specifically for eyelid tumors. However, eyelid lesions are often detected during routine eye examinations, dermatology visits, or primary care appointments when a doctor examines the face and periorbital area. People with risk factors for skin cancer—particularly those with a history of significant sun exposure, prior skin cancer, fair skin, or relevant genetic conditions—should mention any new or changing eyelid lesion to their doctor promptly rather than waiting for a scheduled appointment.

Self-examination is a useful habit. Looking at the eyelids in good lighting and checking for any new lumps, bumps, discolored patches, areas of missing lashes, or changes in existing moles can prompt early medical evaluation. Any eyelid lesion that grows, bleeds, ulcerates, changes color or shape, or causes loss of eyelashes in the affected area should be evaluated by a doctor without delay.

While benign eyelid tumors generally cannot be prevented, the risk of malignant eyelid tumors can be meaningfully reduced with consistent sun protection habits. Preventative steps include:

• Wear UV-blocking sunglasses year-round: Choose wraparound or close-fitting frames that block 99–100% of UVA and UVB rays. The lower eyelid, in particular, receives significant reflected UV radiation and is the most common site for eyelid basal cell carcinoma.
• Wear a wide-brimmed hat outdoors: Hats with a brim of at least 3 inches provide meaningful shade to the face and eyelids.
• Apply broad-spectrum sunscreen: Use sun protection factor (SPF) 30 or higher on the face, including the periorbital area, especially during prolonged outdoor activities. Use sunscreen specifically formulated for use near the eyes.
• Avoid tanning beds: Artificial UV sources significantly increase cumulative UV exposure and skin cancer risk.
• Seek shade during peak UV hours: UV radiation is strongest between 10 am and 4 pm.
• Attend regular skin and eye exams: Annual skin checks by a dermatologist and comprehensive eye exams by an ophthalmologist allow early detection of suspicious lesions before they advance.
• Discuss genetic risk with a specialist: People with a family history of multiple skin cancers, xeroderma pigmentosum, Gorlin syndrome, or Muir-Torre syndrome should seek genetic counseling and follow an enhanced surveillance plan.

The most common reason a person seeks evaluation for an eyelid tumor is noticing a new growth, bump, or change in the appearance of the eyelid. Many eyelid tumors—both benign and malignant—are entirely painless in their early stages. This painlessness is one reason malignant tumors can be mistaken for harmless lesions for months or even years. Any new or changing eyelid growth deserves medical attention, even if it does not hurt.

Signs and symptoms that may indicate an eyelid tumor include:

• A new lump, bump, or nodule on the eyelid: may be flesh-colored, red, pink, brown, black, or purple depending on the tumor type. May be smooth, pearly, crusted, scaly, or warty.
• A lesion with rolled or raised edges: a classic feature of basal cell carcinoma, which often has a pearly, raised border with small blood vessels visible on the surface.
• An ulcer or sore on the eyelid that does not heal: A non-healing ulceration or crusted wound is a warning sign of malignancy, particularly BCC or SCC.
• Loss of eyelashes in one area (madarosis): When a tumor destroys the follicles from which lashes grow, localized lash loss appears. This is a particularly important warning sign for sebaceous gland carcinoma, which can spread along the lid margin and eliminate lashes in a patch.
• A pigmented lesion that is changing: A mole or dark spot on the eyelid that is growing, changing color, developing irregular borders, or bleeding should be evaluated urgently for melanoma.
• Recurrent or treatment-resistant chalazion: A chalazion (a firm, painless lump caused by a blocked meibomian gland) that keeps returning in the same location, or that does not respond to standard treatment, should be biopsied to rule out sebaceous gland carcinoma.
• Thickening or induration of the eyelid: A firm area within the eyelid tissue that does not move freely may indicate a deeper tumor.
• Redness, scaling, or chronic irritation of the eyelid margin: When blepharitis-like symptoms occur persistently in one area, particularly without responding to usual blepharitis treatment, sebaceous gland carcinoma or other malignancy should be considered.
• Eyelid notching or deformity: As a tumor grows and invades surrounding tissue, it can distort the normal contour of the eyelid margin.
• Vision changes or double vision: When an eyelid tumor is large enough to press on the eye or when a malignancy invades the orbit (eye socket), it can affect vision and eye movement.
• Swollen lymph nodes in front of the ear or under the jaw: Regional lymph node swelling may indicate spread of a malignant eyelid tumor beyond the eyelid itself and requires urgent evaluation.

An ophthalmologist, oculoplastic surgeon (an ophthalmologist who specializes in the tissues around the eye), or dermatologist evaluates and diagnoses eyelid tumors. Clinical examination can often give a strong indication of whether a lesion is likely benign or malignant, but a tissue biopsy—removing a small sample of the lesion for examination under a microscope—is required to make a definitive diagnosis. This is especially important before any surgical treatment, because the correct operation depends on knowing the exact tumor type. Delaying biopsy of a suspicious eyelid lesion is not advisable, as some aggressive tumors—particularly sebaceous gland carcinoma—can spread significantly while being treated as a benign condition.

• Clinical examination: The doctor examines the eyelid under magnification, assessing the lesion’s size, shape, color, borders, surface texture, and relationship to the eyelid margin and lashes. The entire eyelid, conjunctival surface, regional lymph nodes, and surrounding facial skin are assessed. Clinical features alone can strongly suggest the diagnosis in many cases.
• Slit-lamp biomicroscopy: A specialized eye microscope that is used to examine the eyelid margin, conjunctival surface, and the cornea in fine detail. It can reveal tumor involvement of the inner eyelid lining and any effects on the eye’s surface.
• Incisional biopsy: A small portion of the lesion is surgically removed and sent to a pathologist (a doctor who examines tissue under a microscope). Used when the lesion is large, when complete removal could be disfiguring, or when the diagnosis is unclear before deciding on the extent of surgery.
• Excisional biopsy: The entire lesion is removed for pathological examination. Used for smaller lesions where complete removal is feasible and appropriate as both a diagnostic and therapeutic step.
• Map biopsies (conjunctival map biopsy): used specifically when sebaceous gland carcinoma is suspected. Multiple small biopsies are taken from different areas of the conjunctival surface of both eyelids to detect pagetoid spread—the microscopic spread of tumor cells along the conjunctiva beyond what is visible on examination. This technique determines the full extent of disease before planning surgery.
• Mohs micrographic surgery with intraoperative frozen section: a specialized surgical technique in which the tumor is removed layer by layer, with each layer examined under a microscope while the patient waits. This allows the surgeon to confirm that all cancer cells have been removed while sparing as much healthy tissue as possible. It is particularly valuable for eyelid tumors because of the tight space and functional importance of the tissue.
• Imaging studies: Computed tomography (CT) or magnetic resonance imaging (MRI) of the orbit and surrounding structures is ordered when the tumor is large, when orbital invasion is suspected, or when regional lymph node involvement or distant spread needs to be assessed. CT is better for evaluating bony orbital walls; MRI provides superior soft tissue detail.
• Sentinel lymph node biopsy: used for melanoma and occasionally Merkel cell carcinoma to determine whether cancer cells have spread to the nearest lymph nodes, guiding decisions about additional systemic treatment.

The treatment for an eyelid tumor depends entirely on whether it is benign or malignant, what tissue type it arose from, how large it is, and whether it has spread beyond the eyelid. Benign tumors that are not causing symptoms or functional problems can often be left alone and monitored. Malignant tumors require surgical removal with confirmed clear margins—meaning the entire tumor, with a rim of healthy tissue around it, has been excised. Because the eyelid serves critical functions in protecting the eye and maintaining the tear film, reconstructing the eyelid after tumor removal requires careful surgical planning to preserve both appearance and function. Your surgeon will discuss the specific approach that is most appropriate for your type and stage of tumor.

For benign eyelid tumors—including papillomas, seborrheic keratoses, cysts, and moles that are growing, irritating the eye, or causing cosmetic concern—simple surgical excision in the office or operating room under local anesthesia is the standard treatment. The lesion is removed and sent for pathological confirmation that it is indeed benign. Small benign growths can also be treated with cauterization (burning), cryotherapy (freezing), or laser ablation when appropriate. Dermoid cysts require complete surgical removal, including their full capsule, to prevent recurrence and the inflammatory reaction that follows rupture.

Malignant eyelid tumors require surgical excision with clear margins as the cornerstone of treatment. For basal cell carcinoma and squamous cell carcinoma of the eyelid, Mohs micrographic surgery is often the preferred technique when available. In Mohs surgery, the tumor is removed in thin layers, each of which is examined under a microscope immediately, while the patient waits. The surgeon continues removing tissue only in areas where cancer cells remain, until the entire tumor is confirmed to have been cleared. This approach achieves the highest cure rates while removing the least possible amount of healthy eyelid tissue—an important consideration given the functional importance of the eyelid and the limited tissue available for reconstruction. After tumor removal, eyelid reconstruction is performed during the same procedure or shortly after. The reconstructive technique depends on how much of the eyelid was removed—small defects may close directly, while larger defects may require flaps of adjacent skin or grafts of tissue from another site, such as the inner arm, behind the ear, or the opposite eyelid. The goal of reconstruction is to restore a functional, comfortable eyelid that fully protects the eye surface. For sebaceous gland carcinoma, wide excision with map biopsy-guided margins is required because of the tumor’s tendency to spread in ways that are not visible on the surface. In some cases where pagetoid spread is extensive, the conjunctiva of one or both eyelids must be treated. Adjuvant (additional) cryotherapy to the conjunctival surface is sometimes used after surgical resection. For malignant melanoma of the eyelid, wide local excision with sentinel lymph node biopsy is performed. When spread to lymph nodes or distant organs is confirmed, systemic treatments including targeted therapy (such as BRAF inhibitors for BRAF-mutated melanoma) and immunotherapy (such as checkpoint inhibitors including pembrolizumab and nivolumab) are used in coordination with a medical oncologist. Merkel cell carcinoma of the eyelid is treated with wide excision, sentinel lymph node biopsy, and radiation therapy to the tumor site and regional lymph nodes. Immunotherapy with avelumab or pembrolizumab is used for metastatic disease. In rare cases where a malignant eyelid tumor has invaded the orbit—the bony socket containing the eye—orbital exenteration (surgical removal of the entire orbital contents, including the eye) may be necessary. This is a major procedure reserved for cases where less radical surgery cannot achieve tumor control. Radiation therapy is used as a primary treatment for patients who are not surgical candidates, as adjuvant therapy after surgery for high-risk tumors, or for palliative care when a cure is not achievable.

Discovering a tumor on the eyelid—whether benign or malignant—is an unsettling experience. For the majority of people whose eyelid tumors are benign, the path forward involves a straightforward procedure and reassuring follow-up. For those diagnosed with a malignant eyelid tumor, the outlook depends heavily on the type of cancer and how early it was caught. Basal cell carcinoma—by far the most common eyelid cancer—is highly curable when removed completely. Squamous cell carcinoma and sebaceous gland carcinoma require prompt, thorough surgery and careful follow-up monitoring, but are also frequently cured when treated at an early stage. Melanoma and Merkel cell carcinoma require close coordination with oncology specialists and regular imaging to monitor for spread. After eyelid reconstruction, most patients are satisfied with both the functional and cosmetic results. It is important to protect the treated area from further sun exposure and to attend all follow-up appointments—local recurrence of malignant eyelid tumors is possible, and catching it early makes a significant difference in outcomes. If you notice any change in the treated area or develop a new growth elsewhere on the eyelid or face, let your care team know promptly.

To further your understanding of your diagnosis and to contribute to cutting-edge research, consider participating in a clinical trial so clinicians and scientists can learn more about causes, symptoms, treatment, and prevention of eyelid tumors and related disorders. Clinical research uses human volunteers to help researchers learn more about a disorder and perhaps find better ways to safely detect, treat, or prevent disease.

All types of volunteers are needed—those who are healthy or may have an illness or disease—of all different ages, sexes, races, and ethnicities to ensure that study results apply to as many people as possible, and that treatments will be safe and effective for everyone who will use them.

To learn more about clinical trials and find studies that may be right for you, visit National Institutes of Health (NIH) Clinical Research Trials and You and ClinicalTrials.gov to search active studies by condition, location, and age group.